Vivo Bio Tech
18.30
-0.25(-1.35%)
Market Cap₹40.61 Cr
PE Ratio-14.53
IndustryHealthcare
Company Performance:
1D-1.35%
1M0.00%
6M0.00%
1Y0.00%
5Y0.00%
View Company Insightsright
More news about Vivo Bio Tech
14Jul 26
Vivo Bio Tech approves director re-appointment, related party deals
Vivo Bio Tech Ltd shareholders have approved the re-appointment of Mr. Kalyan Ram Mangipudi as Whole-time Director and sanctioned related party transactions involving a promoter appointment and dealings with M/s. Virinchi Limited. The resolutions were passed via a postal ballot process that concluded on July 14, 2026, with the requisite majority as per the scrutinizer's report.
 no imag found
29Jun 26
Vivo Bio Tech Ltd appoints Bhavish Vijayvargiya as Company Secretary
Vivo Bio Tech Ltd appointed Bhavish Vijayvargiya as Company Secretary and Compliance Officer effective June 24, 2026, following the resignation of Mr. A V Kiran. The Board meeting to approve this appointment commenced at 4:00 P.M. and concluded at 4:20 P.M. The company clarified the omission of meeting timings in a subsequent filing to BSE Limited on June 29, 2026.
 no imag found
13Jun 26
Vivo Bio Tech seeks nod for ₹30 crore related party transactions
Vivo Bio Tech has initiated a postal ballot process for shareholder approval on the re-appointment of Mr. Kalyan Ram Mangipudi as Whole-time Director and two related party transactions, including a ₹30 crore annual limit with Virinchi Limited. The company also seeks approval to appoint Mrs. Madhavi Latha Kompella as an Advisor for Strategy & Business Development. Remote e-voting is scheduled from June 15, 2026, to July 14, 2026, with the cut-off date for eligibility on June 05, 2026.
 no imag found
02Jun 26
Vivo Bio Tech reports FY26 net loss, publishes results
Vivo Bio Tech Limited reported a consolidated net loss of ₹170.88 lakh for FY26, a reversal from the net profit of ₹728.26 lakh in the previous year, while total income increased to ₹5,377.55 lakh. The board approved the audited results, re-appointed Mr. Kalyan Ram Mangipudi as Whole-time Director, and noted outstanding statutory dues of approximately ₹419.29 lakh.
 no imag found
13Apr 26
Vivo Bio Tech Limited Reports Zero Physical Share Transfer Requests for March 2026
Vivo Bio Tech Limited reported zero physical share transfer requests for March 2026 under SEBI's special re-lodgement window. The compliance report, filed with BSE on April 13, 2026, shows no requests were received, processed, approved, or rejected during the month. The report was prepared by registrar Aarthi Consultants Private Limited in accordance with SEBI Circular dated January 30, 2026.
 no imag found
07Apr 26
Vivo Bio Tech Limited Submits Dematerialization Compliance Certificate for Q1 FY27
Vivo Bio Tech Limited submitted its dematerialization compliance certificate to BSE for January-March 2026 period on April 07, 2026. The filing, required under SEBI Regulation 74(5), was supported by confirmation from Registrar M/s. Aarthi Consultants Private Limited that all dematerialization processes were completed within regulatory timeframes, including certificate cancellation and record updates.
 no imag found
09Jan 26
Vivo Bio Tech Promoter Group Member Acquires 90,000 Equity Shares Through Warrant Conversion
Kompella Lopa Mudra, promoter group member of Vivo Bio Tech Limited, acquired 90,000 equity shares through warrant conversion on January 06, 2026. The transaction maintained total shareholding at 3.09% while restructuring the holding pattern between direct equity and warrants. The company's equity capital increased from ₹22.10 crores to ₹22.19 crores following the preferential allotment.
 no imag found
08Jan 26
Virinchi Limited Allots 86 Lakh Convertible Equity Warrants to Vivo Bio Tech
Virinchi Limited has completed the allotment of 86 lakh convertible equity warrants to Vivo Bio Tech Limited following Stakeholders Relationship Committee approval on January 8, 2026. The preferential issue at ₹28 per warrant generated ₹6.02 crores upfront payment, with full conversion potentially increasing promoter group shareholding from 37.51% to 42.34%.
 no imag found
06Jan 26
Vivo Bio Tech Limited Allots 90,000 Equity Shares Through Warrant Conversion
Vivo Bio Tech Limited allotted 90,000 equity shares at ₹45 each through warrant conversion to promoter group member Kompella Lopa Mudra, raising ₹30.38 lakh. The allotment increased the company's share capital to ₹22.19 crore with 2,21,90,628 total equity shares.
 no imag found
20Aug 25
Vivo Bio Tech Secures ₹10.75 Crore Pre-Clinical Testing Contract for Novel Molecule
Vivo Bio Tech Limited has secured a pre-clinical testing contract worth ₹10.75 crores with a leading Indian pharmaceutical and agro-chemical company. The two-year contract involves comprehensive pre-clinical safety and regulatory studies for a novel molecule, including toxicity, mutagenicity, ecotoxicology studies, and analytical services. The studies will be conducted under Section 9(3) requirements for submission to the Central Insecticides Board & Registration Committee (CIBRC). This contract positions Vivo Bio Tech among top Contract Research Organizations in India, demonstrating its capability to deliver integrated pre-clinical solutions meeting national and international regulatory standards.
 no imag found
14Aug 25
Vivo Bio Tech Reports Strong Q1 FY2026 Performance with 29.66% Revenue Growth
Vivo Bio Tech Limited announced robust Q1 FY2026 results. Total income increased by 29.66% to Rs. 2,220.72 lakhs. Profit After Tax rose by 21.93% to Rs. 155.72 lakhs. Earnings Per Share improved to Rs. 1.05. Operating Profit Margin increased to 9.04%. The company published its un-audited financial results in English and Telugu newspapers on August 14, 2025.
 no imag found
04Aug 25
Vivo Bio Tech Shareholders Approve Increase in Authorized Share Capital
Vivo Bio Tech Limited secured shareholder approval to increase its authorized share capital and alter the Capital Clause of its Memorandum of Association. The resolution passed with 99.81% votes in favor, with a 31.47% overall participation rate. The Promoter and Promoter Group showed 100% support with a 68.78% participation rate. This approval could enable the company to raise additional funds, potentially for growth strategies or expansion plans.
 no imag found
Vivo Bio Tech
18.30
-0.25
(-1.35%)
1 Year Returns:0.00%
Industry Peers
Anthem Biosciences
924.50
(+3.52%)
Advanced Enzyme Tech
295.35
(+0.43%)
CCME Global
35.91
(-5.00%)
Vivo Bio Tech
18.30
(-1.35%)